Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR‐mutated lung cancer

Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR‐mutated lung cancer

Abstract Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) have become the gold standard for EGFR‐mutated non‐small cell lung cancer (NSCLC) treatment. Immune checkpoint inhibitors (ICIs) have been developed for the treatment of several malignancies, including lung c...

Full description

Bibliographic Details
Main Authors: Takashi Ito, Hiromi Nagashima, Masachika Akiyama, Yu Utsumi, Hideomi Sato, Shinji Chiba, Mayu Sugai, Kenji Ube, Yoshiaki Mori, Kana Watanabe, Tatsuro Fukuhara, Makoto Maemondo
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:Thoracic Cancer
Subjects:
EGFR mutation
EGFR tyrosine kinase inhibitor
immune checkpoint inhibitor
L858R mutation
non‐small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.14267

Internet

https://doi.org/10.1111/1759-7714.14267

Similar Items